Equasens Société anonyme (EQS) H2 2024 earnings summary

Executive summary

• Q4 2024 marked a return to growth with revenue up 2.6% sequentially, driven by recurring activities and SaaS transition, despite a challenging environment.

• Annual revenue reached €216.8m, down 1.4% year-over-year, with recurring revenues partially offsetting a sharp decline in hardware and equipment sales.

• Net profit attributable to shareholders declined 23% to €36.2m, and current operating income fell 19.2% to €45.1m, reflecting margin pressure and continued investment.

• Profit margins improved over the year, with current operating income/revenue rising from 19.3% in H1 to 22.3% in H2.

• Strategic focus on SaaS migration, AI-driven innovation, and external growth to secure future performance.

Financial highlights

• Revenue: €216.8m in 2024, down 1.4% year-over-year; Q4 revenue at €58.6m, the second-best quarterly result.

• Current operating income: €45.1m (20.8% of sales), down from €55.8m in 2023.

• Net profit: €36.2m, down 23% year-over-year; EPS at €2.41 vs €3.13 in 2023.

• Net cash position/financial surplus: €79.5m at year-end, with a net-debt-to-equity ratio of -33.0%.

• Cash flow after interest and tax: €46.9m, with increased dividend distributions and investments.

Outlook and guidance

• Double-digit growth targeted for 2025, with acceleration expected in H2.

• Growth drivers include SaaS migration, AI integration, new product launches (TITANLINK, ASCA Dynamics, CALIMED), and expansion in the UK.

• Continued R&D and product innovation, with a focus on interoperability and care coordination.

• Profitability will remain solid but impacted by ongoing investments in innovation and expansion.